Cabozantinib (BMS-907351)

For research use only. Not for use in humans.

目录号：S1119 别名： XL184 中文名称：卡博替尼

Cabozantinib (BMS-907351) Chemical Structure

CAS No. 849217-68-1

Cabozantinib (XL184, BMS-907351)是一种有效的VEGFR2抑制剂，在无细胞试验中IC50为0.035 nM，也能有效抑制c-Met、 Ret、 Kit、Flt-1/3/4、Tie2和AXL，IC50分别为1.3 nM，4 nM，4.6 nM，12 nM/11.3 nM/6 nM，14.3 nM 和 7 nM。Cabozantinib 在结肠癌细胞中可通过AKT/GSK-3β/NF-κB信号通路诱导PUMA依赖的凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1800.41	现货
5mg	RMB 902.82	现货
50mg	RMB 3837.48	现货
200mg	RMB 8176.22	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Cabozantinib (BMS-907351)发表文献94篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Discov, 2018, 8(7):836-849

PubMed: 29657135 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Discov, 2014, 4(7):816-27

PubMed: 24771846 ( click the link to review the publication )

Clin Cancer Res, 2021, 27(9):2533-2548

PubMed: 33619172 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3635

PubMed: 34298852 ( click the link to review the publication )

Front Oncol, 2021, 11:663517

PubMed: 33954115 ( click the link to review the publication )

Sci Rep, 2021, 11(1):12466

PubMed: 34127734 ( click the link to review the publication )

Molecules, 2021, 26(16)4949

PubMed: 34443536 ( click the link to review the publication )

J Pharm Biomed Anal, 2021, 205:114343

PubMed: 34500236 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Angiogenesis, 2021, 10.1007/s10456-021-09771-z

PubMed: 33629198 ( click the link to review the publication )

Nat Commun, 2020, 1;11(1):2124

PubMed: 32358507 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-3608

PubMed: 32034073 ( click the link to review the publication )

Clin Cancer Res, 2020, 20 pii: clincanres

PubMed: 32312893 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.1610.2020

PubMed: 33148676 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )
Cancers (Basel), 2020, 12(12)E3816

PubMed: 33348809 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2838

PubMed: 33019652 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):E1401

PubMed: 32485915 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Oral Oncol, 2020, 112:105074

PubMed: 33142224 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(8):1176-1188

PubMed: 32461304 ( click the link to review the publication )

Mol Cancer Res, 2020, 1176-1188

PubMed: None ( click the link to review the publication )

Dis Model Mech, 2020, dmm.047779

PubMed: 33318047 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Commun Biol, 2020, 3(1):776

PubMed: 33328556 ( click the link to review the publication )

NPJ Precis Oncol, 2020, 4:21

PubMed: 32802958 ( click the link to review the publication )

Life Sci, 2020, 247:117402

PubMed: 32035930 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2019, 101021/acsami9b20178

PubMed: 31816241 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(6):830-844

PubMed: 30929576 ( click the link to review the publication )

Int J Cancer, 2019, 145(7):1991-2001

PubMed: 30848481 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):43

PubMed: 30898150 ( click the link to review the publication )

Cell Death Dis, 2019, 10(3):201

PubMed: 30814510 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0043

PubMed: 31527225 ( click the link to review the publication )

Oncogenesis, 2019, 8(2):7

PubMed: 30647407 ( click the link to review the publication )
J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(9)

PubMed: 31027376 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114768

PubMed: 31639374 ( click the link to review the publication )

Future Oncol, 2019, 15(22):2585-2593

PubMed: 31339066 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Oncotarget, 2019,

PubMed: 30863492 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(10):1753-1765

PubMed: 31279006 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4821

PubMed: 30446652 ( click the link to review the publication )

Sci Rep, 2018, 8(1):4177

PubMed: 29520051 ( click the link to review the publication )

Cell Signal, 2018, 51:191-198

PubMed: 30075184 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Regen Eng Transl Med, 2018, 4(3):120-132

PubMed: 30417074 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 30038711 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(20):6239-6253

PubMed: 28698200 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 17(3):603-613

PubMed: 29237806 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1533-1542

PubMed: 28795691 ( click the link to review the publication )

Cell Signal, 2017, 29:138-149

PubMed: 27777072 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(7):473-483

PubMed: 28475408 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

Anticancer Res, 2017, 37(11):6125-6132

PubMed: 29061793 ( click the link to review the publication )
Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2094-104

PubMed: 26893478 ( click the link to review the publication )

Cancer Lett, 2016, 376(2):218-25

PubMed: 27060207 ( click the link to review the publication )

Cancer Discov, 2016, 6(12):1334-1341

PubMed: 27694386 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2851-62

PubMed: 25977330 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):122-32

PubMed: 25955731 ( click the link to review the publication )

Mol Imaging, 2015, 13(0):1-5

PubMed: 25248353 ( click the link to review the publication )

Chem Biol, 2015, 22(4):504-515

PubMed: 25865310 ( click the link to review the publication )

Nat Commun, 2014, 5:3116

PubMed: 24445538 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1471

PubMed: 25321478 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Liver Int, 2014, 10.1111/liv.12524

PubMed: 24621440 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:1107-23

PubMed: 25170251 ( click the link to review the publication )

Genes Genomics, 2014, 36(6):829-841

PubMed: 25530832 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7945-59

PubMed: 25277206 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e627

PubMed: 23661005 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 377(1-2):1-6

PubMed: 23811235 ( click the link to review the publication )

Surgery, 2012, 152(6):1238-47

PubMed: 23158190 ( click the link to review the publication )

产品安全说明书

VEGFR抑制剂选择性比较

生物活性

产品描述

靶点

VEGFR2/KDR ^[1] (Cell-free assay)	c-Met ^[1] (Cell-free assay)	Axl ^[1] (Cell-free assay)
0.035 nM	1.3 nM	7 nM

体外研究

XL184是多种受体酪氨酸激酶小分子抑制剂，尤其抑制c-Met 和VEGFR2。XL-184也有效作用于Ret, Kit, FLT1, FLT3, FLT4, Tie2, 和 AXL ， IC50分别为 4 nM, 4.6 nM, 12 nM, 11.3 nM, 6 nM, 14.3 nM, 和7 nM。XL184微弱抑制 RON 和PDGFR-β，IC50分别为 124 nM和 234 nM,而对FGFR1则几乎没有抑制活性，IC50 为5.294 μM。^[1] XL184低浓度(0.1-0.5 μM) 时处理MPNST细胞，也显著抑制组成型和诱导型Met磷酸化及其下游信号，且抑制 HGF诱导的MPNST细胞迁移和侵袭。XL184作用于细胞因子刺激的人脐静脉内皮细胞（HUVECs），也显著抑制Met和VEGFR2磷酸化。虽然XL184浓度为0.1 μM时不能抑制MPNST细胞生长，但是浓度为5-10 μM 时则能显著抑制MPNST细胞生长。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
E98NT	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUm3SIo3OC5yMT2xNEDPxE1?		MWHEUXNQ	MkPaTWM2OD16OTDuUS=>	M{TTWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi0NFA3Lz5{M{S4OFAxPjxxYU6=
SNU-5	NYHmcmVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRSBzOTDuUS=>	Ml75QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
Hs746T	NWTLfWJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rWUGlEPTB;OT65JI5O	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{NkG5NUc,OjF7Mk[xPVE9N2F-
SNU-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLpTWM2OD13MkKzJI5O	NYe1cYZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
SNU-16	MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTFzNEmgcm0>	NXX2SIRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
MDA-MB-231	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFGxUGtKSzVyPTC2OFIyKG6P	NF:4RZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlE6OSd-MkG5NlYyQTF:L3G+
U87MG	NGfCbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXUR29KSzVyPUG4OVEhdk1?	NXnFNnBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
H441	NGrET5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\FNHNsUUN3ME2yNVcxOCCwTR?=	Ml:1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
H69	Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;ESIJKSzVyPUKwNlAxKG6P	NIi0b2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlE6OSd-MkG5NlYyQTF:L3G+
PC3	MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTFyOECwJI5O	NEDxSHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlE6OSd-MkG5NlYyQTF:L3G+
MTC-TT	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLETWM2OD1yLkC0JEshOC5yMzFOwG0>	Mne1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2N{C5PVUoRjJzNEewPVk2RC:jPh?=
MZ-CRC	NVzONY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHhRoNKSzVyPjC1JO69VQ>?	NYXTO5hrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0O\|A6QTVpPkKxOFcxQTl3PD;hQi=>
TPC-1	NVHlPFZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfUZYdKSzVyPUCuNFYhMyByLkCyJO69VQ>?	M4X2N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEewPVk2Lz5{MUS3NFk6PTxxYU6=
NIH-3T3/TPR-Met	M3K3W2Z2dmO2aX;uJIF{e2G7				MlnHTY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iaX6gcY92e2ViTlnIMVNVOy:WUGKtUYV1KGOnbHzzMEBKSzVyIE2gNUDPxE1w	M4fGVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm2NVQ1Lz5{NEm5OlE1PDxxYU6=
BA/F3	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M1HDeGlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIG\FS2ZTOiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wLDDHTVUxKD1iMD6wNFMh\|ryPLh?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BaF3	M2fqeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmL5OFghcHK\|		MlrUTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiUnX0JHM5QTGDIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYV[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwMEGg{txONg>?	M3\HXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
BA/F3	NGW4WodIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3fOcFQ5KGi{cx?=		NV2zTWZwUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgWGVNNW[3c3XkJHJGXCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkC1JO69VS5?	NX70cYd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
TT	Mo\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGS2cGcyOCCmYYnz		NXj1UXZ2UW6qaXLpeIlwdiCxZjDSSXQhSzZ\|NGegcZV1[W62IHnuJIh2dWGwIGTUJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhOTBiZHH5d{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkGyJO69VS5?	NEDqb2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
BA/F3	NHPOfIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnvvOFghcHK\|		M3fMRWlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIGLleEBXQDB2TTDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iMD64PUDPxE1w	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BaF3	M{ntR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYrzc49CPDhiaILz		M2raT2lvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIGLleEBXQDB2TDDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQnHGN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkmxJO69VS5?	NGDPOXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
Nthy-ori 3-1	MUPDfZRwfG:6aXPpeJkh[XO\|YYm=		MkLMNVAh\GG7cx?=		NGXkVJpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPfGi7LX;ybUA{NTFiY3XscJMh[W[2ZYKgNVAh\GG7czDifUBOXFRiYYPzZZktKEeLNUCgQUA1Njl\|IN88UU4>	NGO2dYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
BAF3	MoHXSpVv[3Srb36gZZN{[Xl?	NVHKNoFkOC5yMTD0c{AyOCC3TR?=	NV;NZpI2OSCqch?=		Mn\VTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRid3ns[EB1gXCnIGLleEApfW6tbn;3ckBwemmpaX6pJJBpd3OyaH;yfYxifGmxbjDheEB[OTB4Mj;ZPVA2KGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHH0JFAvODFidH:gNVAhfU1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	M4nUTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
TT	NIXyTWxHfW6ldHnvckBie3OjeR?=		NXnUe2g4PCCqcoO=		MnHBTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJHJGXCCFNkO0W{BufXSjboSgZZQhYTlyNTDpckBpfW2jbjDUWEBk\WyuczDheEAyKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BAF3	NU\4SoNsTnWwY4Tpc44h[XO\|YYm=	M4XOWFAvODFidH:gNVAhfU1?	NGDYVo0yKGi{		MWTJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCUZYSgV\|g6OUFibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkheGixc4Doc5J6dGG2aX;uJIF1KFlzME[yM3k6ODViZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZQhOC5yMTD0c{AyOCC3TTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BAF3	NFLL[XZHfW6ldHnvckBie3OjeR?=	NFrHO5ExNjBzIITvJFExKHWP	Mk[0NUBpeg>?		NV;nSHA5UW6qaXLpeIlwdiCxZjDUSWwu\nW\|ZXSgVoV1KFN6OUHBJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGmxbjDv[kBRVEOpYX3tZUBifCC\N{izJIF1KDBwMEGgeI8hOTBidV2gZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NUnHNpp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
BAF3	NH2w[oVHfW6ldHnvckBie3OjeR?=	NHfxe5UxNjBzIITvJFExKHWP	Moq5NUBpeg>?		NFe5N4lKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDS[ZQhWzh7MVGgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMhe3WycILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1cW:wIH;mJHNp[yCjdDDZN\|E4KGG2IECuNFEhfG9iMUCgeW0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M{PuOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
TT	NV7Md5Y5TnWwY4Tpc44h[XO\|YYm=	MkjCNUB1dyBzMDD1US=>	M3PoS\|QhcHK\|		NUDuRpdZUW6qaXLpeIlwdiCxZjDSSXQhSzZ\|NGegcZV1[W62IHnuJIh2dWGwIGTUJINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIGDMR4didW2jIIDoc5NxcG:{eXzheIlwdiCjdDDZO\|g{KGG2IEGgeI8hOTBidV2gZYZ1\XJiNDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT	NGP0WXpHfW6ldHnvckBie3OjeR?=	M4DT[lEhfG9iMUCgeW0>	NGfvWVU1KGi{cx?=		M4HqOGlvcGmkaYTpc44hd2ZiUlXUJGM3OzSZIH31eIFvfCCrbjDoeY1idiCWVDDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHQzODJxWUKwOEBifCBzIITvJFExKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NHfkcnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
TT	MWjGeY5kfGmxbjDhd5NigQ>?	Mn7UNUB1dyBzMDD1US=>	M{HOdVQhcHK\|		NEj4eW5KdmirYnn0bY9vKG:oIGLFWEBEPjN2VzDteZRidnRiaX6gbJVu[W5iVGSgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbjDheEBVOzB6L2O0O\|Mh[XRiMTD0c{AyOCC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	MnL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT	M4rXfmZ2dmO2aX;uJIF{e2G7	MlLENUB2VQ>?			NGjmeW9KdmirYnn0bY9vKG:oIGLleE1lemm4ZX6gc45kd2enbnnjJJRz[W6\|Zn;ycYF1cW:wIH;mJIh2dWGwIGTUJINmdGy\|IHH0JFEhfU1iYomgd49nfCCjZ3HyJIF{e2G7	NF33SGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
TT	M3TDdmZ2dmO2aX;uJIF{e2G7	MXKxJJVO	NXHNTmh1PCCqcoO=		MmTiTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJHJGXCCFNkO0W{BufXSjboSgZZQhYTFyNkKgbY4hcHWvYX6gWHQh[2WubIOgZZQhOSC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NHX1TW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
TT	MmTIRZBweHSxc3nzJIF{e2G7	MYSxJJVO	NIH0VVU6PiCqcoO=		M4TTUWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iVGSgZ4VtdHNiZYjwdoV{e2mwZzDS[ZQhSzZ\|NGegcZV1[W62IHH0JFEhfU1iYX\0[ZIhQTZiaILzJIJ6KGGwbnX4bY5XN1CLIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndILpZ{BidmGueYPpdy=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
PC3	NFTk[HpHfW6ldHnvckBie3OjeR?=		MmnWNUB1dyB\|IHjydy=>		M4S4N2lvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEOyClZXzsd{BqdmO3YnH0[YQh\m:{IEGgeI8hOyCqcoOsJGlEPTBiPTCxMlkh\|ryPLh?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjdzN{KwNUc,OjZ5MUeyNFE9N2F-
MDA-MB-231	NVH3fXQxTnWwY4Tpc44h[XO\|YYm=		MV2xJJRwKDNiaILz		M{XyfmlvcGmkaYTpc44hd2ZiQWjMJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhOSC2bzCzJIhzeyxiSVO1NEA:KDVizszNMi=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjdzN{KwNUc,OjZ5MUeyNFE9N2F-
BAF3	MmXCSpVv[3Srb36gZZN{[Xl?		MorONUB1dyB\|IHjydy=>		M2DsbGlvcGmkaYTpc44hd2ZiRlzUN{ApfW6tbn;3ckBwemmpaX6pJJBpd3OyaH;yfYxifGmxbjD0doFve2[nY4Tl[EBqdiCvb4Xz[UBDSUZ\|IHPlcIx{KGmwY4XiZZRm\CCob4KgNUB1dyB\|IHjyd{whUUN3MDC9JFcvPSEQvF2u	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjdzN{KwNUc,OjZ5MUeyNFE9N2F-
MDA-MB-231	NF;jSnBHfW6ldHnvckBie3OjeR?=		MWWxJJRwKDNiaILz		M{HufGlvcGmkaYTpc44hd2ZiS1nUJEh2dmuwb4fuJI9zcWerbjmgdIhwe3Cqb4L5cIF1cW:wIITyZY5{\mWldHXkJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgbY5kfWKjdHXkJIZweiBzIITvJFMhcHK\|LDDJR\|UxKD1iNEKg{txONg>?	M3TOcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{G3NlAyLz5{NkexO\|IxOTxxYU6=
BA/F3	MnPYSpVv[3Srb36gZZN{[Xl?		NULESppTPDhiaILz		NEDXb3dKdmirYnn0bY9vKG:oIFvEVkApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IFPlcIwhfGm2cnWg[4xwNWKjc3XkJIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODF2IN88UU4>	NIHq[2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki3OFc1OSd-Mk[4O\|Q4PDF:L3G+
Sf21	MnvVSpVv[3Srb36gZZN{[Xl?		NF;ocIQyPSCvaX7z		MlTjTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDIbZMufGGpZ3XkJIh2dWGwIFvEVkBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB{MDDtbY5{KGK7IFjUVmYh[XO\|YYmsJGlEPTBiPTCwMlAyPiEQvF2u	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh5NEe0NUc,OjZ6N{S3OFE9N2F-
BA/F3	MnjiSpVv[3Srb36gZZN{[Xl?		M3jKfFQ5KGi{cx?=		NVW0OFczUW6qaXLpeIlwdiCxZjDLTWY2Si:URWSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCFZXzsJJRqfHKnIHfsc{1j[XOnZDDseY1qdmW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlE6KM7:TT6=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh5NEe0NUc,OjZ6N{S3OFE9N2F-
BA/F3	MWLGeY5kfGmxbjDhd5NigQ>?		MoLqOFghcHK\|		MYrJcohq[mm2aX;uJI9nKEuLRkXCM3JGXCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JGNmdGxidHn0doUh\2yxLXLhd4VlKGy3bXnu[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMUmg{txONg>?	NHXWN4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki3OFc1OSd-Mk[4O\|Q4PDF:L3G+
BA/F3	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2fESlczKGi{cx?=		NF;q[VVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochXFCULV3leEBi\nSncjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFAvODJzOTFOwG0v	MmW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNki4PFkoRjJ5ME[4PFg6RC:jPh?=
Sf21	MWLGeY5kfGmxbjDhd5NigQ>?		MUe2NEBucW6\|		MnTSTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViTj30[ZJucW6jbDDHV3QufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJHJGXCBqNkW4JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNidYPpcocheG:ueTjHcJUtXHm{KUS6NUBieyC\|dXLzeJJifGViaX7jeYJifGWmIH\vdkA3OCCvaX7zJIJ6KEWOSWPBMEBKSzVyIE2gNE4xODNizszNMi=>	NIDqcW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN\|ExPjZ:L3G+
Sf21	MUHGeY5kfGmxbjDhd5NigQ>?		NWDrcGdbPjBibXnudy=>		MX\Jcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiR2PUMZRi\2enZDDy[YNwdWKrbnHueEBpfW2jbjDSSXQhXjhyNF2gcZV1[W62IDi2OVghemW\|aXT1[ZMqKGW6cILld5Nm\CCrbjDpcpNm[3RiU3[yNUBk\WyuczD1d4lv\yCyb3z5LGdtfSyWeYKpOFoyKGG\|IIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDZyIH3pcpMh[nliRVzJV2EtKEmFNUCgQUAxNjhzMTFOwG0v	NV73OoRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|ExPjZpPkK3NVMyODZ4PD;hQi=>
BaF3	Mme5SpVv[3Srb36gZZN{[Xl?		MXS3NkBpenN?		MVHJcohq[mm2aX;uJI9nKEOFRFO2MXJGXCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYV[zJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjh6OTFOwG0v	NUDFeFJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|ExPjZpPkK3NVMyODZ4PD;hQi=>
BaF3	NGfVc5RHfW6ldHnvckBie3OjeR?=		M{X4e\|czKGi{cx?=		NGWyT5BKdmirYnn0bY9vKG:oIFPDSGM3NVKHVDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCZWY{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLki4PUDPxE1w	Mmr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Ba/F3	NVnabW5vTnWwY4Tpc44h[XO\|YYm=				MWLJcohq[mm2aX;uJI9nKFKHVDCoeY5sdm:5bjDvdolocW5rIITyZY5{\mWldHXkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygS2k2OCB;IECuNFch\|ryPLh?=	NGfveZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixOFU3OCd-Mke4NVQ2PjB:L3G+
TT	NXnWU4lzTnWwY4Tpc44h[XO\|YYm=				MoHJTY5pcWKrdHnvckBw\iCURWSgR\|Y{PFdibYX0ZY51KGmwIHj1cYFvKFSWIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygS2k2OCB;IECuNlYh\|ryPLh?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzNEW2NEc,Ojd6MUS1OlA9N2F-
Ba/F3	MYfGeY5kfGmxbjDhd5NigQ>?				NH\C[4pKdmirYnn0bY9vKG:oIGLFWEBXQDB2TTDteZRidnRiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwY3WgZZN{[XluIFfJOVAhRSByLke0JO69VS5?	NIDBUow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixOFU3OCd-Mke4NVQ2PjB:L3G+
Nthy-ori 3-1	MULDfZRwfG:6aXPpeJkh[XO\|YYm=				MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOeIh6NW:{aTCzMVEh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdmOnIHHzd4F6NCCJSUWwJF0hOi57MjFOwG0v	M3:5e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEG0OVYxLz5{N{ixOFU3ODxxYU6=
HepG2	MYrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF31bos4OiCqcoO=		MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCxNkDPxE1w	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzMkG1PUc,Ojh2MUKxOVk9N2F-
EBC1	MnOwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mne1O\|IhcHK\|		NV\2blBISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA2OTRizszNMi=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzMkG1PUc,Ojh2MUKxOVk9N2F-
H1299	NGT0bHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUS3NkBpenN?		M4DQ[mdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGgyOjl7IHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUAyNjlzOTFOwG0v	NInsSnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[1NVk4QSd-Mki2OVE6Pzl:L3G+
MCF7	NUXHeXFST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWi3NkBpenN?		MXXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNR2Y4KGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTCyMlg5QSEQvF2u	NITRUVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[1NVk4QSd-Mki2OVE6Pzl:L3G+
A549	NEjlZo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEH2coQ4OiCqcoO=		M1z0bmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFQvOjB3IN88UU4>	M1XyUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
T47D	M2CxOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mo\xO\|IhcHK\|		MVTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDUOFdFKGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTC0MlQ1QCEQvF2u	M4q5dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
H460	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXi3NkBpenN?		NFfpe\|BIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJPDZyIHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUA2NjZ4OTFOwG0v	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O\|k9N2F-
HuH7	M3H1RWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3PtNlQ5KGi{cx?=		MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEi3SEegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDRwM{S4JO69VS5?	M{PKOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEW3NFQzLz5{OUC1O\|A1OjxxYU6=
A498	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmjnOFghcHK\|		MnrvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEm4JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB6LkS1OkDPxE1w	MnfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyNUewOFIoRjJ7MEW3NFQzRC:jPh?=
NCI-H727	M3\3TGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXmwdlZvPDhiaILz		M3O2cGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg4OjdiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE1NjBzIN88UU4>	NXr5dWZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwOVcxPDJpPkK5NFU4ODR{PD;hQi=>
BAF3	NGqxWW5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXO3NkBpenN?		NF3DNWhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJHRTWC2PRWSgZYZ1\XJiN{KgbJJ{KGK7IFPDT{05KGG\|c3H5MEBKSzVyIE2gNE4xOjRizszNMi=>	NUnUNoRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFY1PTJpPkK5NVQ3PDV{PD;hQi=>
A549	NFrVfoZEgXSxdH;4bYNqfHliYYPzZZk>	MVuxNEB2VQ>?	NYTzSHBqPzJiaILz		Mn21R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BifCBzMDD1UUBi\nSncjC3NkBpenNiYomgTY5kfWO7dHWgcIl3\S2lZXzsJIlu[WerbnegZY5idHm\|aYO=	M4TPO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVY{Lz5{OUSwO\|k3OzxxYU6=
A673	NV7WWnJleUiWUzDhd5NigQ>?				MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MVTxTHRUKGG\|c3H5				NI\2fpNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MkC4dWhVWyCjc4PhfS=>				M4PRZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	NGjCTJpyUFSVIHHzd4F6				M3PBdJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	NGm1cXlyUFSVIHHzd4F6				MX7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	M3;JZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NYjNfm1xeUiWUzDhd5NigQ>?				NITFOG9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	MmTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	NUfFV5hHeUiWUzDhd5NigQ>?				MnzMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	MnLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	NHnldGdyUFSVIHHzd4F6				MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MkPwdWhVWyCjc4PhfS=>				NXK3O\|JveUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NFnEOmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MkT3dWhVWyCjc4PhfS=>				M3TCW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	NVfNZY4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	MmTadWhVWyCjc4PhfS=>				M1rlU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	MoX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	MoTidWhVWyCjc4PhfS=>				NYe5SXRTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	NIjJdG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	M4rOTpFJXFNiYYPzZZk>				NF\jcHNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBQUFNvNUCgZ4VtdHN?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	M{DVWZFJXFNiYYPzZZk>				M4XieZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM>	MnHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	M3jFSJFJXFNiYYPzZZk>				MknWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	M2jySZFJXFNiYYPzZZk>				MoLPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	M3zXSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NEn6bGNyUFSVIHHzd4F6				MlG5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	M3nESFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NFPGeolyUFSVIHHzd4F6				NWHie3Y3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	MXPxTHRUKGG\|c3H5				NWfOb2p4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	NIfYNYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	M4m3[JFJXFNiYYPzZZk>				NInIN5JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUi2JQl2yJINmdGy\|	M2fWdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	NGPifmtyUFSVIHHzd4F6				NWXvWYQ2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	M1PBU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	M2\GUJFJXFNiYYPzZZk>				MkjLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV4Fwey1{IHPlcIx{	NVLkcYxURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
EBC1	NY\L[WppSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGLTNJY4OiCqcoO=		M1\mdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNFQ5KM7:TT6=	NVHvTHpGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyOFg3PTRpPkOwNlQ5PjV2PD;hQi=>
MKN45	NEfTfZpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2TqXVczKGi{cx?=		NXnOT\|FJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNT241PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xODZ7IN88UU4>	MoXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
SNU5	M4rB[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1PXc\|czKGi{cx?=		M2nL[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU17VOUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNVIyKM7:TT6=	M3r2WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkS4OlU1Lz5\|MEK0PFY2PDxxYU6=
BAF3	M1fMPWZ2dmO2aX;uJIF{e2G7		M4j1XlczKGi{cx?=		NYT1dIZ6UW6qaXLpeIlwdiCxZjDUVHIufGGpZ3XkJI1mfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCxPVg3KM7:TT6=	Mki2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
NCI-H460	Mm[yRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnTxO\|IhcHK\|		MkjIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xPDBzIN88UU4>	MkTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
MGHU3	MoO1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVK3NkBpenN?		M4P2VmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVfIWVMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYm=	NWXCeI8{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzNFk3PzFpPkOwN\|A6PjdzPD;hQi=>
RT112	M{m4T2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4fJbFczKGi{cx?=		NUWxd4kySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSWFEyOiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfS=>	MkjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|MEm2O\|EoRjNyM{C5OlcyRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-MET(Y1234/1235) / MET / p-EGFR(Y1068) / EGFR / p-Gab1(Y627) / Gab1 / p-AKT(S473) / p-ERK / p-EIF4E; PubMed: 29188469 Invest New Drugs MET kinase inhibitors but not emibetuzumab inhibited MET signaling pathway in Hs746t cells in vitro by western blot analysis. Hs746t cells were treated for 24 h with 133 nM (20 μg/ml) or 667 nM (100 μg/ml) emibetuzumab or MET kinase inhibitors (merestinib, PF04217903, crizotinib, cabozantinib) at 15.6, 62.5, 250 or 1000 nM. p-MET / p-ERK / p-AKT; PubMed: 29520051 Sci Rep Western blot analysis of cellular pathways modifications after CBZ 5 μM treatment in HOS, MG-63, Saos-2 and U-2 OS cells; (A) CBZ 5 μM inhibits c-MET phosphorilation after 1 hour of treatment; downstream ERK activation kinetic adopts a sigmoidal shape in all OS cell lines, whereas AKT activation is strongly inhibited in HOS, Saos-2 and U-2OS, but not in MG-63 cells.	29188469 29520051
Immunofluorescence	α-tubulin; PubMed: 29520051 Sci Rep Immunostaining of mitotic spindle in control and CBZ 5 μM treated HOS cells using a monoclonal antibody against α-tubulin (in green); white arrows indicate the mitotic spindle poles; control cells show normal bipolar spindles during metaphase formation, whereas treated cells show tripolar spindles during prometaphase (II), metaphase (III) and anaphase (IV); bar scale = 10 μm.	29520051
Growth inhibition assay	Cell viability; PubMed: 23661005 Cell Death Dis Cells were left untreated or were treated with 5, 7.5 or 10 μM cabozantinib (XL184). Seventy-two hours later viability was detected by MTT-assay and apoptosis by staining with annexinV-FITC followed by FACS-analysis.	23661005

体内研究

XL184按 30 mg/kg 剂量处理携带自发胰岛细胞瘤的RIP-Tag2 小鼠，扰乱 83%肿瘤血管, 降低周细胞和空基底膜袖，引起广泛瘤内缺氧和广泛的肿瘤细胞凋亡，且停药后延缓肿瘤血管再生长，与XL999相比更显著抑制VEGFR而不是c-Met，导致血管降低43％，说明抑制VEGFR，也抑制放大抑制血管新生的其他功能相关的受体酪氨酸激酶（RTK）。XL184也降低原发肿瘤的侵袭和减少转移。^[1] XL184 每天按30 mg/kg剂量处理SCID小鼠，显著废除人 MPNST移植瘤生长和转移。^[2] XL184 处理乳腺癌，肺癌胶质瘤模型，抑制肿瘤生长，这种作用存在剂量依赖性，降低肿瘤和内皮细胞增殖，促进凋亡。XL184按100 mg/kg 和 10 mg/kg剂量分别单独处理携带MDA-MB-231肿瘤的小鼠和携带C6肿瘤的大鼠，持续抑制肿瘤生长。^[3]

细胞实验： ^[2]	- 合并 Cell lines: ST88-14, STS26T, 和MPNST724 Concentrations: 溶于DMSO,终浓度~10 μM Incubation Time: 48小时 Method: 使用不同浓度XL184处理细胞48小时。通过MTS实验使用CellTiter96 Aqueous 非放射性细胞增殖实验试剂盒测定细胞生长。然后在 490 nm处测定吸光值。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带自发胰岛肿瘤的RIP-TAG2转基因小鼠。 Dosages: ~60 mg/kg Administration: 口服饲喂 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	100 mg/mL (199.39 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Cabozantinib (BMS-907351) SDF

分子量	501.51
化学式	C₂₈H₂₄FN₃O₅
CAS号	849217-68-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	XL184

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04957160	Not yet recruiting	--	Advanced Renal Cell Carcinoma (aRCC)	Ipsen	September 4 2021	--
NCT04868773	Recruiting	Drug: Cabozantinib\|Drug: TAS-102	Colorectal Cancer\|Colorectal Carcinoma\|Metastatic Cancer\|CRC	University of California Irvine	July 2021	Phase 1
NCT04893785	Not yet recruiting	Drug: Cabozantinib and Temozolomide	Lung Neuroendocrine Neoplasm\|GEP Neuroendocrine Tumor	National Cancer Institute Naples	June 2021	Phase 2
NCT04804813	Recruiting	Drug: Cabozantinib	Renal Cell Carcinoma	Takeda	March 29 2021	--
NCT04631744	Recruiting	Drug: Cabozantinib	Prostate Cancer	Weill Medical College of Cornell University\|Exelixis	March 3 2021	Phase 2
NCT04300140	Recruiting	Drug: AVB-S6-500\|Drug: Cabozantinib (Cabo)	Clear Cell Renal Cell Carcinoma	Aravive Inc.	February 26 2021	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

泛VEGFR抑制剂

Regorafenib (BAY 73-4506) : Pan-VEGFR inhibitor, VEGFR1/VEGFR2/VEGFR3, IC50=13 nM/4.2 nM/46 nM.
活性最高的VEGFR抑制剂

Axitinib : VEGFR1, VEGFR2, VEGFR3, IC50=0.1 nM, 0.2 nM, 0.1-0.3 nM.
FDA批准的VEGFR抑制剂

Axitinib : Approved by FDA for Renal Cell Carcinoma.
经典的VEGFR抑制剂

Dovitinib (TKI-258, CHIR-258) : Multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM.

研究领域

产品类型

定制您的化合物库

Cabozantinib (BMS-907351)

客户使用Selleck生产的Cabozantinib (BMS-907351)发表文献94篇：

产品安全说明书

VEGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Cabozantinib (BMS-907351) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

相关VEGFR产品